Selank + Semax 10 mg/10 ml Spray
$64.92$72.13 (-10%)
Selank + Semax 10 mg/10 ml Spray is a multi-component research listing containing the named peptide identities. Each component requires its own identity and quantity specification; the finished mixture has no single peptide sequence or universal molecular formula. A Selank/Semax blend contains two named peptide identities. A single total quantity does not establish how much of each component is present, and a Selank reference result cannot be used as a result for Semax. This listing uses a spray-format presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.
Selank + Semax 10 mg/10 ml Spray Australia
Selank + Semax 10 mg/10 ml Spray is listed at AU Peptides Shop in a spray-format presentation. This page brings together the compound identity, reference chemistry and laboratory considerations relevant to this specific catalogue entry. It is intended exclusively for controlled in vitro laboratory research, not personal use.
Product description
Selank
Selank is a synthetic heptapeptide associated with tuftsin-derived peptide research. Its seven-residue identity distinguishes it from Semax, even though the two names often appear together in catalogue blends. Sequence confirmation and formulation composition are separate parts of sample characterisation.
A Selank/Semax blend contains two named peptide identities. A single total quantity does not establish how much of each component is present, and a Selank reference result cannot be used as a result for Semax.
Semax
Semax is a synthetic heptapeptide related to an adrenocorticotropic-hormone fragment with a Pro-Gly-Pro extension. Its defined sequence distinguishes it from the separately named Selank peptide. The complete name is preferable to the ambiguous abbreviation Sem when selecting a chemical reference.
Sem may be used for different compounds in catalogues and is not treated as a reliable automatic identity. Semax data are assigned only to a confirmed Semax listing, and a two-component spray requires separate specifications for each named peptide.
Chemical information and molecular structure
This is a multi-component material. A single molecular formula, molecular weight or peptide sequence cannot describe the complete preparation. Each identified component requires its own reference, while the mixture requires a component and quantity specification.
| Reference designation | Selank |
|---|---|
| Selected reference species | Selank |
| Reference molecular formula | C33H57N11O9 |
| Reference molecular weight | 751.9 g/mol |
| Reference identifier | PubChem CID 11765600 |
| Sequence information | Multiple components; use component-specific sequence records. |
View the reference molecular structure in PubChem. The referenced structure identifies a database species; it is not a structural analysis or certificate for the supplied Selank + Semax 10 mg/10 ml Spray.
| Reference designation | Semax |
|---|---|
| Selected reference species | ACTH (4-7), Pro-Gly-Pro- |
| Reference molecular formula | C37H51N9O10S |
| Reference molecular weight | 813.9 g/mol |
| Reference identifier | PubChem CID 9811102 |
| Sequence information | Multiple components; use component-specific sequence records. |
View the reference molecular structure in PubChem. The referenced structure identifies a database species; it is not a structural analysis or certificate for the supplied Selank + Semax 10 mg/10 ml Spray.
Reference formula and molecular weight depend on the represented chemical species. Counterions, hydration, oxidation state, terminal modifications and formulation ingredients can change the relationship between a database molecule and the supplied material. Use the named reference species for structural comparison, and use the batch specification for the actual product composition.
Research applications and experimental scope
- Heptapeptide identity and chromatographic evaluation.
- Comparisons of peptide sequence modifications.
- Controlled cell-system research.
- Analytical assessment of Selank-containing mixed preparations.
- Identity testing of an ACTH-fragment-related peptide.
- Sequence and impurity profiling.
- Controlled peptide–cell model evaluation.
- Stability and matrix-recovery studies.
These are laboratory research topics and analytical objectives, not claims that the supplied product has achieved a biological result. Define the experimental question, model and acceptance criteria before comparing materials. A literature observation made with a different sequence, formulation or model cannot establish the performance of this catalogue item.
Analytical characterisation
For Selank + Semax 10 mg/10 ml Spray, a multi-component method must distinguish the named ingredients rather than report only a total chromatographic area. Consider component-specific reference standards, separation selectivity and recovery from the combined matrix. A dominant peak from one ingredient may obscure another ingredient or a degradation product.
Document individual component amounts and the basis on which they are reported. A nominal blend total is not a measured amount for every constituent. If components share analytical signals, use an orthogonal identity approach or a validated separation before assigning the result. Keep the mixture specification separate from the specifications for its individual reference molecules.
Laboratory model and control considerations
An in vitro experiment with Selank + Semax should distinguish the test-material response from effects of the vehicle, assay matrix and any additional ingredients. Include the controls appropriate to the study design, and keep the reference standard and test sample traceable to their own preparation records. Where a readout depends on cell viability or matrix composition, assess those factors independently of the primary measurement.
Record the sample identity, selected product option, preparation history and analytical method used for the comparison. Repeatability within one run does not by itself establish specificity or transferability to another model. Report observations within the limits of the experimental system rather than treating an in vitro result as evidence of a clinical benefit.
Supplied format and product specifications
| Product name | Selank + Semax 10 mg/10 ml Spray |
|---|---|
| Catalogue format | spray-format presentation |
| Quantity wording in listing | 10 mg / 10 ml |
| Purity / certification | Refer to the relevant batch report; no percentage or certification is assigned without product documentation. |
A spray-format product is a finished presentation. Total ingredient mass, total liquid volume and any documented actuation specification are separate measurements. Do not describe the finished spray as lyophilized powder or infer an amount per actuation from the bottle title alone. Formulation components can affect laboratory sample recovery and assay interference.
Solubility and matrix compatibility
For Selank + Semax, use product-specific solubility information and a laboratory method appropriate to the selected presentation. Apparent dispersion is not necessarily complete dissolution, and a visually clear preparation does not establish chemical stability. Assess recovery and matrix compatibility using the measurement required for your experiment.
Where the product contains additional ingredients, distinguish dissolution of the reference compound from extraction of the finished formulation. Record the documented matrix and any observed interference so another analyst can interpret the result. No universal solvent, solubility limit or preparation protocol is assigned from this catalogue name.
Storage and handling
Use the storage conditions specified for the supplied Selank + Semax 10 mg/10 ml Spray batch and presentation. A universal freezer temperature, refrigeration interval or prepared-sample expiry is not assigned from the compound name alone. Obtain the relevant product guidance when storage or sample stability is an acceptance criterion for your work.
Maintain traceable labels and document the handling history relevant to the study. Assess changes in appearance, analytical profile or recovery against a validated method rather than assuming that an unchanged label establishes stability. Aseptic laboratory technique does not by itself demonstrate that a research product is sterile; sterility and related quality attributes require their own evidence.
Related catalogue comparisons
- Semax 5 mg — Shares a named component; composition differs.
- Selank 5 mg — Shares a named component; composition differs.
Compare the exact compound, form and quantity in each linked listing. These catalogue relationships do not establish interchangeable materials or recommend combined use.
Australian research enquiries
For Selank + Semax 10 mg/10 ml Spray in Australia, include the complete listing name, required option and any analytical documentation requirements when you contact AU Peptides Shop. Browse the research catalogue for other individually specified materials. Current purchasing options show price and availability; batch evidence should be reviewed separately.
Scientific references
Research compliance notice
For controlled in vitro laboratory research only. Not for human or veterinary use. This description provides scientific reference information and does not recommend dosing, administration or treatment. Research-use labelling does not establish regulatory approval or permission for a particular activity under Australian therapeutic-goods requirements.
